Analytical Data
-
Gene name
FLT3LG
- Application
-
Alternative Names
SL cytokine
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P49771
-
Expression Region
27-184aa
-
Molecular Weight
33.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FLT3LG (Fms-like Tyrosine Kinase 3 Ligand) is a crucial cytokine involved in hematopoiesis and immune system regulation, particularly in the growth and differentiation of hematopoietic stem cells and dendritic cells. The FLT3LG gene encodes a ligand that specifically activates the FLT3 receptor, which plays a significant role in the development of various blood cells. Dysregulation of the FLT3 signaling pathway has been implicated in several hematological malignancies, including acute myeloid leukemia (AML) and other blood cancers, emphasizing the need for therapeutic interventions targeting this pathway. Recombinant FLT3LG protein has gained attention in recent years as a potential agent for enhancing the immune response against tumors and improving the efficacy of immunotherapies. Research has shown that FLT3LG can promote the expansion of dendritic cells, which are vital for initiating and regulating adaptive immunity. Additionally, studies suggest that modulating FLT3LG levels could improve the outcomes of cancer treatments by fostering a robust antitumor immune response. Therefore, the development and characterization of recombinant FLT3LG protein are of significant interest in both basic research and clinical applications, aiming to explore its therapeutic potential in treating malignancies and advancing cell-based immunotherapies. Understanding the functional properties and biological implications of FLT3LG will not only enhance our knowledge of immune system dynamics but also pave the way for novel treatment strategies in oncology and other diseases involving immune dysregulation.
